Literature DB >> 15332706

Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains.

E Tortoli1, D Dionisio, C Fabbri.   

Abstract

The new quinolone moxifloxacin was tested against 86 strains of Mycobacterium tuberculosis including 13 resistant and 4 multiresistant strains. The antimicrobial susceptibility was tested, in parallel, using two different liquid media, the radiometric Bactec 12B and the Mycobacteria Growth Indicator Tube (Becton Dickinson, USA). All strains but two were susceptible at 0.5 microg/ml of moxifloxacin; for the remaining two strains, both multidrugresistant, the minimal inhibitory concentrations (MIC) were =2 and >4 microg/ml respectively. Our data confirm the high antitubercular in vitro activity of moxifloxacin.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15332706     DOI： 10.1179/joc.2004.16.4.334

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


  9 in total

1.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Authors:  Melisa Willby; R David Sikes; Seidu Malik; Beverly Metchock; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

4.  Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates.

Authors:  Jakko van Ingen; Sami Simons; Rina de Zwaan; Tridia van der Laan; Miranda Kamst-van Agterveld; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

5.  Testing susceptibility of multidrug-resistant Mycobacterium tuberculosis to second-line drugs by use of blood agar.

Authors:  Dilek Satana; Ahmet Yilmaz Coban; Meltem Uzun
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

6.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279

7.  Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea.

Authors:  Bo Hyoung Kang; Kyung-Wook Jo; Tae Sun Shim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-03-31

8.  Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for in vivo Evaluation of Drug Regimens.

Authors:  Frida Arrey; Delia Löwe; Stefanie Kuhlmann; Peggy Kaiser; Pedro Moura-Alves; Gopinath Krishnamoorthy; Laura Lozza; Jeroen Maertzdorf; Tatsiana Skrahina; Alena Skrahina; Martin Gengenbacher; Geraldine Nouailles; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

9.  Chemotherapeutic interventions against tuberculosis.

Authors:  Neeraj Shakya; Gaurav Garg; Babita Agrawal; Rakesh Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.